Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989;23(2):123-5.
doi: 10.1007/BF00273532.

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

Affiliations

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

S Tura et al. Cancer Chemother Pharmacol. 1989.

Abstract

In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed after other chemotherapy. PTT was scheduled by escalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR + PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

PubMed Disclaimer

Similar articles

Cited by

References

    1. G Ital Chemioter. 1985 Jan-Apr;32(1):1-6 - PubMed
    1. Ann Intern Med. 1976 Oct;85(4):417-22 - PubMed
    1. Farmaco Sci. 1983 Apr;38(4):205-18 - PubMed
    1. Ann Intern Med. 1983 Mar;98(3):304-9 - PubMed
    1. Biochem Pharmacol. 1985 Jul 1;34(13):2347-54 - PubMed

Publication types

LinkOut - more resources